Pharma major Biocon is set to announce its Q3FY26 results on 12 Feb 2026. Brokerage reports project a strong Q3FY26 for ...

Viatris is letting go of the equity stake it’s held in Biocon’s biosimilar subsidiary Biocon Biologics for $815 million, allowing Biocon to fully integrate its subsidiary. The Viatris stake is one of ...

Overall Count and Share for 'Biocon Bristol-Myers Squibb Research and Development Center (BBRC)' based on the 12-month time frame mentioned above. Note: Articles may be assigned to more than one ...

MUMBAI, Sept 27 (Reuters) - Biocon Ltd said on Monday it had strengthened its existing research partnership with Cuba-based Center of Molecular Immunology (CMI) to create a product pipeline focused on ...

Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...

As an update to our previous report, Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) announced the successful completion of the transition of the acquired biosimilars business in approximately 120 ...

Biocon Biologics, a subsidiary of Biocon, received a European Union GMP certificate from the Health Products Regulatory Authority (HPRA), Ireland, for its new monoclonal antibodies (mAbs) drug ...

BANGALORE, April 19 (Reuters) - India's largest biotechnology firm, Biocon Ltd. , sees strong growth in the current fiscal year on new drug discovery and large research outsourcing services contracts, ...

MUMBAI (MarketWatch) -- Biocon Ltd. (532523.BY), an Indian biotechnology company, Wednesday said that its unit, Syngene International Pvt. Ltd., has entered into a research tie-up with U.S.-based ...

Article ‘Count’ and ‘Share’ for Biocon Bristol-Myers Squibb Research and Development Center (BBRC) based on listed parameters only. The articles listed below published by authors from Biocon ...